KEY POINTS 27 Question. Do patients with stable atherosclerotic cardiovascular disease treated with statin who have an LDL-C <70 mg/dL and a non-HDL-C > 100 benefit from the addition of evolocumab? Would patients already on maximal potency statin benefit from evolocumab? Findings. Evolocumab safely reduced cardiovascular events compared to placebo whether patients were starting with an LDL-C <70 mg/dL or not, and whether they were treated with maximal potency statin or a less potent statin regimen. Meaning. In high-risk patients with stable atherosclerotic cardiovascular disease treated with a statin, even patients who have a low LDL-C and patients on maximal statin experience further reduction of cardiovascular events with the addition of evolocumab. 37 38
KEY POINTS 27 Question. Do patients with stable atherosclerotic cardiovascular disease treated with statin who have an LDL-C <70 mg/dL and a non-HDL-C > 100 benefit from the addition of evolocumab? Would patients already on maximal potency statin benefit from evolocumab? Findings. Evolocumab safely reduced cardiovascular events compared to placebo whether patients were starting with an LDL-C <70 mg/dL or not, and whether they were treated with maximal potency statin or a less potent statin regimen. Meaning. In high-risk patients with stable atherosclerotic cardiovascular disease treated with a statin, even patients who have a low LDL-C and patients on maximal statin experience further reduction of cardiovascular events with the addition of evolocumab. 37 38
clinical%20efficacy%20-%20FOURIER%20trial%2c%20Giugliano%20RP%20et%20al%2c%20Lancet%202017.docx